STTK Shattuck Labs, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1680367 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-66.6%
TTM net income YoY14.5%
TTM EPS YoY63.6%
Revenue 3-yr CAGR5.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-5,578.7%
Net margin-5,256.8%
FCF margin—
EBITDA margin-5,221.0%
Returns
ROE-39.2%
ROA-36.9%
ROIC (approx.)-57.1%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets4.3%
Debt / equity0.00x
Current ratio27.59x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-8.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $1.00M | $0 | $0 | $0 |
| R&D expense | $21.57M | $11.70M | $10.95M | $9.05M | $7.62M | $8.68M | $9.92M | $15.39M |
| SG&A expense | $5.48M | $4.46M | $4.60M | $4.32M | $4.10M | $4.35M | $4.47M | $4.25M |
| Operating income | -$27.05M | -$16.16M | -$15.54M | -$13.37M | -$10.72M | -$13.03M | -$14.39M | -$19.64M |
| Net income | -$25.20M | -$15.15M | -$14.77M | -$12.59M | -$10.06M | -$12.46M | -$13.70M | -$18.68M |
| EBITDA | -$26.23M | -$15.30M | -$14.65M | -$12.45M | -$9.80M | -$12.10M | -$13.45M | -$18.73M |
| EPS (basic) | -0.14 | -0.12 | -0.13 | — | -0.14 | -0.24 | -0.27 | — |
| EPS (diluted) | -0.14 | -0.12 | -0.13 | — | -0.14 | -0.24 | -0.27 | — |
| Weighted avg. shares (diluted) | 183.22B | 129.78M | 112.23M | — | 72.18B | 51.00M | 50.97M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $61.76M | $63.30M | $90.42M | $54.19M | $42.55M | $50.47M | $60.90M | $57.39M |
| Current assets | $201.60M | $213.27M | $93.75M | $82.47M | $90.72M | $54.67M | $66.40M | $79.22M |
| PP&E, net | $3.63M | $4.51M | $5.35M | $6.11M | $7.05M | $7.95M | $8.88M | $9.81M |
| Total assets | $207.97M | $220.67M | $102.12M | $91.03M | $100.33M | $64.37M | $77.17M | $91.05M |
| Current liabilities | $12.76M | $7.73M | $4.25M | $7.05M | $5.34M | $5.34M | $7.32M | $8.92M |
| Total liabilities | $14.31M | $9.53M | $6.29M | $8.64M | $7.09M | $7.35M | $9.58M | $11.42M |
| Shareholders' equity | $193.66M | $211.14M | $95.83M | $82.39M | $93.24M | $57.02M | $67.59M | $79.63M |
| Shares outstanding | 101.83M | 100.73M | 75.58M | 63.28M | 63.15M | 47.90M | 47.90M | 47.71M |
| Cash flow statement | ||||||||
| Operating cash flow | -$17.47M | -$10.19M | -$13.42M | -$8.49M | -$8.93M | -$10.43M | -$12.03M | -$17.37M |
| Capital expenditure | $50,000 | — | — | $0 | $71,000 | — | — | $0 |
| Free cash flow | -$17.52M | — | — | -$8.49M | -$9.00M | — | — | -$17.37M |
| Investing cash flow | $11.73M | -$144.95M | $23.85M | $20.00M | -$43.49M | $0 | $15.60M | $31.00M |
| Financing cash flow | $4.20M | $128.01M | $25.80M | $134,000 | $44.50M | $0 | -$57,000 | -$72,000 |
| Depreciation & amortization | $813,000 | $851,000 | $891,000 | $918,000 | $917,000 | $929,000 | $936,000 | $911,000 |
| Stock-based compensation | $3.30M | $2.73M | $2.42M | $1.61M | $1.78M | $1.89M | $1.72M | $1.85M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.